I

Impiricus

Builds physician engagement software for pharma

Vice President of Strategic Partnerships - Pharma / Martech

Full-Time
$150k - $500k/yr
Expert
Remote in USA
RemoteRemote is always an option; in-person collaboration encouraged if located near an office.
Sales & Account ManagementAccount Management

About the job

Requirements
  • The candidate must have 10 or more years of experience in sales, partnerships, or business development with a proven ability to build and grow multi-million-dollar accounts.
  • The candidate must have established and trusted relationships with key decision-makers at top 20 pharmaceutical manufacturers.
  • The candidate must demonstrate a strategic mindset with a track record of identifying opportunities, structuring strategic deals, and aligning business solutions with client objectives.
  • The candidate must possess leadership qualities with the ability to influence stakeholders across all levels of an organization.
  • The candidate must have a drive for growth, exhibiting a high-energy, results-oriented approach with a relentless focus on account expansion and revenue generation.
Responsibilities
  • Drive Revenue Growth by leveraging 10+ years of sales experience and a broad industry network to exceed quotas and expand business with top 20 pharmaceutical companies.
  • Develop and Expand Accounts by building and growing client portfolios valued at $5 million or more, with a focus on expansion and long-term impact rather than maintenance.
  • Strategic Alignment by identifying and aligning new business opportunities with client goals and Impiricus’s platform capabilities for maximum value creation.
  • Key Account Ownership by leading and managing high-value client relationships across all levels of the client hierarchy, including C-suite executives, senior leaders, and agency partners.
  • Leverage Networks by applying a strong, well-established network of decision-makers within the pharmaceutical industry to accelerate growth and strengthen partnerships.

About the company

Impiricus sells AI software and customized physician engagement campaigns to pharmaceutical companies, connecting doctors with treatment resources and support. Its Pulse product sends approved information through messaging channels, while Ascend connects conversations to sales representatives and automates follow-up. The platform uses signals from physician interactions to choose relevant communications and route requests to the appropriate client team. Clients use the service to coordinate outreach across brands and territories, and Impiricus earns revenue from this business-facing engagement work. Founded in 2020, Impiricus is headquartered in Atlanta, Georgia.

Company Size

201-500

Company Stage

Early VC

Total Funding

$4.6M

Headquarters

Sandy Springs, Georgia

Founded

2020

Get referred to Impiricus

See people who can refer or advise you

Simplify Jobs

Simplify's Take

What believers are saying

  • Revenue momentum is documented: Impiricus reported 11,691% growth from 2022 to 2025 in August 2026.
  • An internship opened a permanent analytics role: Impiricus names Khawaja Ahmed as a former intern turned data analyst.
  • Commercial scope extends into fulfillment: September 2026's Medvantx integration adds sample management and therapy access to Ascend.

What critics are saying

  • Sampling depends on outside infrastructure: QPharma validates eligibility, enforces compliance and orchestrates Impiricus request fulfillment.
  • AI engineers juggle broad responsibilities: Impiricus combines model evaluation, security and cloud deployment in one role.
  • Client service leaders carry renewal targets: Impiricus assigns retention, expansion and high-risk escalations to account directors.

What makes Impiricus unique

  • Physician reach is unusually exclusive: Impiricus says roughly 30% of underserved doctors engage only through its network.
  • Clinical voices shape product decisions: Impiricus names practicing physicians across specialties on its advisory board.
  • Spark targets clinical moments: prescription, laboratory and diagnosis signals trigger physician outreach.

Help us improve and share your feedback! Did you find this helpful?

Benefits

  • Health Insurance
  • Dental Insurance
  • Vision Insurance
  • Life Insurance
  • Unlimited Paid Time Off
  • 401(k) Company Match

Growth & Insights and Company News

Headcount

6 month growth

3%

1 year growth

8%

2 year growth

1%
Dailyhunt
Oct 16th, 2026
Impiricus earns two national workplace honors from Fortune Media and Great Place To Work.

Impiricus earns two national workplace honors from Fortune Media and Great Place To Work. 1 hour ago Atlanta, Georgia, October 16th, 2026, FinanceWire Fortune Media and Great Place To Work have recognized Impiricus with two national workplace honors, naming the company one of the 2026 Fortune Best Workplaces in Health Care and ranking it No. 8 on this year's list. This marks the second consecutive year Impiricus has earned a place among the nation's Best Workplaces in Health Care, following its No. 17 ranking in 2025. Impiricus also debuted at No. 87 on Fortune's 2026 Best Medium Workplaces list, marking the company's first appearance on the national ranking of the best medium-sized workplaces in the country. The recognition comes during a year of continued momentum for Impiricus, as the company continues to grow at the intersection of healthcare, artificial intelligence, and life sciences. Together, the two 2026 honors underscore Impiricus' commitment to building a high-trust, collaborative workplace and creating an employee experience that scales alongside the organization. The consecutive Best Workplaces in Health Care recognition builds on Impiricus' No. 17 ranking in 2025, while its debut at No. 87 on the Best Medium Workplaces list represents a new milestone for the company. The two national recognitions offer distinct perspectives on Impiricus' workplace culture, one within the health care industry and the other across the broader community of medium-sized companies. Founded by a practicing physician and senior pharmaceutical executive, Impiricus is the first Agentic Commercialization Platform for healthcare. Its agentic AI platform helps life sciences companies connect physicians with relevant clinical resources, patient support, and field teams in real time, transforming healthcare commercialization from information delivery into clinical action. 'Being recognized by Fortune and Great Place To Work with two 2026 Best Workplaces honors is a meaningful reflection of the culture our team is building together,' said Vishwa Patel, EVP of People Operations at Impiricus. 'Both list inclusions reflect our commitment to creating an environment where people feel trusted, supported, and empowered to do their best work. Our team brings tremendous energy and expertise to an incredibly complex challenge, helping life sciences organizations engage physicians in more relevant and meaningful ways. These honors belong to the people who show up every day with curiosity, care, and a genuine commitment to one another and our mission.' The Fortune Best Workplaces in Health Care and Fortune Best Medium Workplaces lists recognize organizations that demonstrate a strong commitment to employee experience and workplace culture. Great Place To Work determines its Best Workplaces lists through its proprietary Trust Index employee survey, capturing employees' perspectives across a range of factors, including trust in leadership, respect, collaboration, support, and workplace culture. The methodology incorporates both the quality and consistency of employees' experiences across roles and demographic groups. To learn more about the lists, visit Great Place To Work 2026 Best Workplaces in Health Care list and 2026 Best Medium Workplaces list. To learn more about Impiricus, visit www.impiricus.com. About Impiricus Impiricus is the first Agentic Commercialization Platform for healthcare. Founded by a practicing physician and a senior pharmaceutical executive, Impiricus is transforming how life sciences companies support physicians while accelerating patient access to life-saving treatments. Powered by the largest opted-in network of healthcare providers, its agentic AI platform delivers the right clinical resources, support, and connections exactly when and where physicians need them. Recognized by Deloitte as the #1 fastest-growing company in North America on the 2025 Technology Fast 500, Impiricus provides the agentic AI infrastructure that transforms healthcare commercialization from information delivery to real-time clinical action. For more information, visit www.impiricus.com. Contact Yilan Yang, Executive Vice President, Marketing and Growth Impiricus [email protected] Disclaimer. This is a paid press release.

USA Today
Aug 25th, 2026
Impiricus launches QPharma(R) integration to power real-time compliant HCP sampling.

Impiricus launches QPharma(R) integration to power real-time compliant HCP sampling. NEW YORK - August 25, 2026 - (KOREWIRE) - Impiricus, the first AI-powered HCP Engagement Engine, today announced an integration with QPharma(R), a leader in PDMA-compliant pharmaceutical sampling and healthcare compliance services. The partnership expands the Impiricus ecosystem, connecting real-time physician engagement with trusted healthcare infrastructure and direct-to-provider sampling solutions. QPharma's Titanium(R) platform and PDMA-compliant sampling infrastructure are now integrated into Impiricus Ascend, the company's agentic commercialization platform. Together, they enable seamless sample requests and fulfillment within real-time conversations across the largest network of more than 1 million opted-in healthcare providers, delivered through each physician's preferred communication channels. For the first time ever, eligible healthcare professionals (HCPs) can request samples from pharmaceutical manufacturers directly within active conversations in SMS, chatbots, intelligent media, and other real-time channels without leaving the workflow. This eliminates disconnected follow-up processes, manual coordination with field teams, and fulfillment delays. "As a specialist physician, the best technology is the kind I hardly notice. If I can access what I need without leaving my workflow or adding another administrative task, that's time and attention I can give back to my patients," said Dr. Iqra Aftab, Rheumatologist. When an HCP expresses interest during an interaction powered by Impiricus Ascend, QPharma technology instantly validates eligibility, enforces PDMA and state compliance requirements, and securely orchestrates fulfillment in real time. The result transforms pharmaceutical sampling from a delayed operational process into immediate access and patient impact. Early pilot results demonstrated strong demand for real-time, workflow-embedded sampling access. Within hours of launch, hundreds of physicians across geographies and time zones requested samples through the experience, including significant engagement during overnight and non-traditional working hours. The response underscored the importance of giving physicians access to critical resources on their own time, at the moment of patient need, whether it's at the point of care, between patients, or during "blue jeans" moments. "Physicians should be able to access critical resources for patients the moment we need them, without navigating fragmented systems or delayed follow-up," said Dr. Osama Hashmi, Dermatologist and CEO of Impiricus. "This partnership with QPharma extends our ability to transform physician engagement into immediate action directly within the clinical workflow. By embedding compliant sampling into physician conversations, our pharmaceutical partners can create experiences that are standardized, compliant, and frictionless across in-office, virtual, and hybrid care environments." For healthcare professionals, the experience is faster, simpler, and fully embedded within existing workflows. Requests can be initiated immediately at the moment of interest, reducing administrative burden while maintaining confidence in compliance and fulfillment integrity. The model is particularly valuable for specialty therapies, virtual-first care environments, and hybrid engagement models where speed, consistency, and compliant access are increasingly critical. "Modern healthcare engagement requires compliant infrastructure that can operate seamlessly across increasingly digital and distributed care environments," said Jitesh Rohatgi, Chief Technology Officer at QPharma. "Together with Impiricus, we are helping life sciences organizations support healthcare professionals and patients with faster, more connected access to samples while maintaining the highest standards of compliance and operational integrity." The announcement reflects Impiricus's broader strategy to build a connected ecosystem of trusted healthcare infrastructure partners capable of transforming physician engagement into real-time action across the healthcare journey. About Impiricus Impiricus is the first Agentic Commercialization Platform for healthcare. Founded by a practicing physician and a senior pharmaceutical executive, Impiricus is transforming how life sciences companies support physicians while accelerating patient access to life-saving treatments. Powered by the largest opted-in network of healthcare providers, our agentic AI platform delivers the right clinical resources, support, and connections exactly when and where physicians need them. Recognized by Deloitte as the #1 fastest-growing company in North America on the 2025 Technology Fast 500(TM), Impiricus provides the agentic AI infrastructure that transforms healthcare commercialization from information delivery to real-time clinical action. Partner with us: https://impiricus.com/ About QPharma Founded in 1994, QPharma is a trusted leader in life sciences compliance, fulfillment, and healthcare professional (HCP) engagement solutions. What began 30+ years ago as a small validation consultancy focused on compliance has evolved into a technology-driven partner supporting pharmaceutical manufacturers across the full lifecycle of sample management and HCP engagement. Today, QPharma combines deep regulatory expertise with innovative, cloud-based technology to help companies simplify operations, strengthen compliance, and improve access to therapy at critical moments of care. Through QPharma's Titanium(R) platform and integrated services, QPharma enables compliant, efficient, and forward-looking solutions that meet the evolving demands of the pharmaceutical industry. Media Contact: Yilan Yang EVP, Marketing & Growth, Impiricus [email protected] Information contained on this page is provided by an independent third-party content provider. XPRMedia and this Site make no warranties or representations in connection therewith. If you are affiliated with this page and would like it removed please contact [email protected]

Associated Press
Aug 25th, 2026
Impiricus integrates QPharma® to enable real-time compliant HCP sampling within physician workflows

Impiricus has integrated QPharma's PDMA-compliant sampling platform into its AI-powered healthcare provider engagement system. The partnership enables physicians to request pharmaceutical samples directly within real-time conversations via SMS, chatbots, and other channels without disrupting their workflow. The integration connects QPharma's Titanium platform with Impiricus Ascend, allowing seamless sample requests across a network of over 1 million opted-in healthcare providers. QPharma's technology validates eligibility and enforces compliance requirements in real time. Early pilot results showed strong demand, with hundreds of physicians requesting samples within hours of launch, including significant engagement during overnight hours. The solution aims to reduce administrative burden whilst maintaining compliance standards. The integration is part of Impiricus's broader strategy to build a connected ecosystem of healthcare infrastructure partners. Impiricus was recognised by Deloitte as the fastest-growing company in North America on the 2025 Technology Fast 500.

Associated Press
Aug 11th, 2026
Impiricus ranks No. 14 on Inc. 5000 with 11,691% growth in AI healthcare commercialisation

Impiricus, an Atlanta-based healthcare technology company, has been ranked No. 14 on the 2026 Inc. 5000 list of America's fastest-growing private companies. The company achieved an 11,691% growth rate over the three-year period. Founded by dermatologist Dr Osama Hashmi, Impiricus builds agentic AI infrastructure for healthcare commercialisation. The platform connects physicians with clinical resources and patient support in real time, aiming to accelerate patient access to treatment. The company was previously recognised as the fastest-growing company in North America on Deloitte's 2025 Technology Fast 500 list. The Inc. 5000 ranking is based on percentage revenue growth from 2022 to 2025, with this year's median growth rate at 130%.

EIN Presswire
Aug 11th, 2026
Impiricus named No 14 on the 2026 Inc. 5000 List, the prestigious ranking of America's fastest-growing private companies.

Impiricus named No 14 on the 2026 Inc. 5000 List, the prestigious ranking of America's fastest-growing private companies. August 11, 2026, 11:00 GMT Company Recognized for 11,691% Three-Year Revenue Growth, Earning a Place Among the Nation's Most Successful Independent Businesses ATLANTA, GA, UNITED STATES, August 11, 2026 / EINPresswire.com / - Impiricus announced today that it has been ranked No. 14 on the 2026 Inc. 5000 list, the annual list of the fastest-growing private companies in America. The list is the most recognized ranking of the nation's most successful independent and entrepreneurial businesses, recognizing companies that have achieved remarkable growth while driving innovation, creating jobs, and shaping the future of the economy. Past honorees include companies such as Microsoft, Meta, Chobani, Oracle, and Patagonia. "Our 11,691% growth rate is a powerful validation of the problem we set out to solve: physicians need less noise and better access to the support that helps them care for patients," said Dr. Osama Hashmi, dermatologist, CEO and co-founder of Impiricus. "Earning the No. 14 spot on the Inc. 5000 reflects the trust we've built with physicians and life sciences leaders, and the extraordinary work of our team. Now we're taking that foundation even further, building agentic AI that turns physician engagement into real-time action and helps patients access treatment faster." Impiricus is building the agentic AI infrastructure for the next generation of healthcare commercialization, transforming physician engagement from information delivery to real-time clinical action. Its technology helps life sciences companies detect physician needs and connect HCPs with relevant clinical resources, patient support, and field teams at the exact time those resources can make a difference. Impiricus programs deliver measurable impact across major therapeutic areas, reaching white-space, digitally dark, and historically underserved physicians, helping accelerate patient access to treatment across the US. "Every company on the Inc. 5000 has a story of perseverance, smart decision making, and a refusal to sit still," says Mike Hofman, editor-in-chief of Inc. "Their growth reflects more than strong financial performance-it reflects creativity, resilience, and the customer focus required to build companies that make a lasting impact. We congratulate all honorees on this significant achievement." This year's Inc. 5000 recognizes a new class of companies redefining what growth looks like. From AI and advanced manufacturing to healthcare, consumer products, and professional services, these businesses are expanding their impact and proving that entrepreneurial ambition continues to fuel the U.S. economy. Among the 5,000 companies on the list, the median three-year revenue growth rate was 130%, and those companies have collectively added more than 627,208 jobs to the U.S. economy over the past three years. For the full Inc. 5000 list, honoree company profiles, and a searchable database by industry and location, please visit: www.inc.com/inc5000. Inc. 5000 List Methodology Companies on the 2026 Inc. 5000 are ranked according to percentage revenue growth from 2022 to 2025. To qualify, companies must have been founded and generating revenue by March 31, 2022. They must be U.S.-based, privately held, for-profit, and independent - not subsidiaries or divisions of other companies - as of December 31, 2025. (Since then, some on the list may have gone public or been acquired.) The minimum revenue required for 2022 is $100,000; the minimum for 2025 is $2 million. As always, Inc. reserves the right to decline applicants for subjective reasons. About Impiricus Impiricus is the first Agentic Commercialization Platform for healthcare. Founded by a practicing physician and a senior pharmaceutical executive, Impiricus is transforming how life sciences companies support physicians while accelerating patient access to life-saving treatments. Powered by the largest opted-in network of healthcare providers, its agentic AI platform delivers the right clinical resources, support, and connections exactly when and where physicians need them. Recognized by Deloitte as the #1 fastest-growing company in North America on the 2025 Technology Fast 500(TM), Impiricus provides the agentic AI infrastructure that transforms healthcare commercialization from information delivery to real-time clinical action. For more information, visit www.impiricus.com. About Inc. Inc. is the leading media brand and playbook for the entrepreneurs and business leaders shaping our future. Through its journalism, Inc. aims to inform, educate, and elevate the profile of its community: the risk-takers, the innovators, and the ultra-driven go-getters who are creating the future of business. Inc. is published by Mansueto Ventures LLC, along with fellow leading business publication Fast Company. For more information, visit www.inc.com. Yilan Yang Impiricus +1 617-485-6582 email us here Legal Disclaimer: EIN Presswire provides this news content "as is" without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the author above. You just read: August 11, 2026, 11:00 GMT EIN Presswire's priority is author transparency. We do our best to weed out false and misleading content. The content above is the sole responsibility of the author who makes it available. If you have any complaints, kindly contact the author above. Yilan Yang +1 617-485-6582